US signals crackdown on compounded weight-loss drugs; Hims shares tumble

Core Viewpoint - The U.S. Food and Drug Administration (FDA) plans to restrict GLP-1 ingredients used in non-approved compounded drugs, impacting companies like Hims & Hers and other compounding pharmacies [1] Group 1 - The FDA's decision is aimed at regulating the use of GLP-1 ingredients in compounded medications, which are often used for weight management and diabetes treatment [1] - This regulatory move may affect the supply chain and availability of certain compounded drugs that utilize GLP-1 ingredients [1] - Companies involved in the production and distribution of these compounded drugs may face operational challenges and potential revenue impacts due to the new restrictions [1]